Winn Awards, the Robert A. Winn Excellence in Clinical Trials Award Program, shared a post by Fox Chase Cancer Center on LinkedIn:
“We are incredibly grateful to Fox Chase Cancer Center for their support and for the generosity of each of our renewed funders – Bristol Myers Squibb Foundation, Gilead Sciences, Genentech, Amgen and AstraZeneca.
As we begin this exciting new chapter together, we look forward to working together to strengthen our programs, expand opportunities for the next generation of clinical investigators, and make an even greater impact on the future of clinical research.
We are excited for what lies ahead!”
Fox Chase Cancer Center, added:
“Fox Chase Cancer Center – Temple Health is proud to become the new institutional home of The Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards), one of the nation’s leading initiatives to improve participation in clinical trials through education, leadership development, and community engagement.
In another important milestone, the Bristol Myers Squibb Foundation, the Winn Awards founding funder, has renewed its commitment that will extend support into the program’s next chapter – as have the program’s additional funding partners Gilead Sciences, Genentech, Amgen and AstraZeneca.
Under the leadership of Robert A. Winn, MD, Cancer Center Director at Fox Chase, we’re excited to continue equipping physician-researchers and clinical trialists to produce Better Science for All.
Learn more: Fox Chase Cancer Center announcement ”
About the Winn Awards’ New Institutional Home
On November 16, 2026, Temple Health announced that Fox Chase Cancer Center would become the new institutional home of the Robert A. Winn Excellence in Clinical Trials Award Program, marking a new chapter in its efforts to expand clinical research education and participation.
Established in 2020 through an initial $100 million commitment from the Bristol Myers Squibb Foundation, the Winn Awards were created to train current and future clinical investigators while improving participation in clinical trials among historically underserved communities.
The Bristol Myers Squibb Foundation has renewed its support through 2030, alongside funding partners Gilead Sciences, Genentech, Amgen and AstraZeneca. These commitments aim to support continued programme development, mentorship and community-focused clinical research.